Richard A Barasch bought $1.4M of Starling Oncology (TOI)
Executed Mar 26 2025, disclosed Mar 28 2025, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Mar 28 2025), the stock returned +164.5% (delay-adjusted); from the execution session (Mar 26 2025), +152.3%. Derived: entry at the session's open, exit at the close 20 sessions later.
Richard A Barasch (Director) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in Starling Oncology Inc (TOI). Across 1 priced purchase filing, the average 21-session return was +152.3% from execution and +164.5% from disclosure (delay-adjusted; derived). The largest single filing was $1.4M of TOI (1,358,448 sh × $1.04, as filed), executed Mar 26 2025.
Healthcare · The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→